CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Eltrombopagdrug
Likely dose
Eltrombopag 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03988608
NCT03988608Phase 2Completed
CompareCT.gov

A Non-randomized, Open-label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Subjects With Refractory or Relapsed Severe Aplastic Anemia

Novartis Pharmaceuticals·interventional·Posted Jun 17, 2019·Updated Dec 30, 2025

In Brief

A Phase 2 clinical trial evaluating Eltrombopag for Aplastic Anemia. Completed, enrolled 20 participants across 5 sites.

Detailed Summary

This was a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag was started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. The hematological response rate was assessed at 3, 6 months and 1 year after starting the study treatment (Week 13, 26 and 52).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAplastic Anemia
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 17, 2019
Enrollment StartDec 9, 2019
Primary CompletionJul 16, 2021
Study CompletionMay 17, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.0 years ago

Interventions

Eltrombopagdrug

Eltrombopag are film-coated tablets containing 25 mg of eltrombopag free acid in each tablet.